Company intelligence / Profile preview

Dualyx

Ghent, Belgiumpharmaceutical-technology.com ↗

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

Dualyx has demonstrated promising preclinical results with its lead program DT‑001, an agonist monoclonal antibody targeting TNF receptor 2 to selectively activate regulatory T cells. IND-enabling studies are underway, aiming to enter clinical proof-of-concept trials. The company’s approach could offer transformative treatments for a broad range of autoimmune conditions by harnessing the immunosuppressive power of regulatory T cells.

Therapeutic areas: Immunology
Modalities: Monoclonal antibodyBiologicMulti-specific antibody
Industry: Biotech

Partnerships

ArgenxVIB

Beyond the preview

Go deeper on Dualyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dualyx.

Explore the full profile